CORT vs. SUPN, TARO, AXSM, PCRX, XNCR, OPK, PRGO, ADCT, AVIR, and JAZZ
Should you be buying Corcept Therapeutics stock or one of its competitors? The main competitors of Corcept Therapeutics include Supernus Pharmaceuticals (SUPN), Taro Pharmaceutical Industries (TARO), Axsome Therapeutics (AXSM), Pacira BioSciences (PCRX), Xencor (XNCR), OPKO Health (OPK), Perrigo (PRGO), ADC Therapeutics (ADCT), Atea Pharmaceuticals (AVIR), and Jazz Pharmaceuticals (JAZZ). These companies are all part of the "pharmaceutical preparations" industry.
Supernus Pharmaceuticals (NASDAQ:SUPN) and Corcept Therapeutics (NASDAQ:CORT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, community ranking, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.
Corcept Therapeutics received 50 more outperform votes than Supernus Pharmaceuticals when rated by MarketBeat users. However, 73.25% of users gave Supernus Pharmaceuticals an outperform vote while only 70.50% of users gave Corcept Therapeutics an outperform vote.
Corcept Therapeutics has lower revenue, but higher earnings than Supernus Pharmaceuticals.
Corcept Therapeutics has a net margin of 21.86% compared to Corcept Therapeutics' net margin of 0.22%. Supernus Pharmaceuticals' return on equity of 21.98% beat Corcept Therapeutics' return on equity.
93.6% of Corcept Therapeutics shares are held by institutional investors. 8.8% of Supernus Pharmaceuticals shares are held by insiders. Comparatively, 20.5% of Corcept Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Corcept Therapeutics had 10 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 13 mentions for Corcept Therapeutics and 3 mentions for Supernus Pharmaceuticals. Corcept Therapeutics' average media sentiment score of 0.56 beat Supernus Pharmaceuticals' score of 0.27 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.
Supernus Pharmaceuticals has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500.
Supernus Pharmaceuticals presently has a consensus target price of $41.00, indicating a potential upside of 34.38%. Corcept Therapeutics has a consensus target price of $39.30, indicating a potential upside of 68.89%. Given Supernus Pharmaceuticals' higher possible upside, analysts clearly believe Corcept Therapeutics is more favorable than Supernus Pharmaceuticals.
Summary
Corcept Therapeutics beats Supernus Pharmaceuticals on 11 of the 15 factors compared between the two stocks.
Get Corcept Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Corcept Therapeutics Competitors List
Related Companies and Tools
